• Product nameAnti-PSAP antibody
    See all PSAP primary antibodies
  • Description
    Mouse monoclonal to PSAP
  • Tested applicationsSuitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein, corresponding to amino acids 18-525 of Human PSAP



Our Abpromise guarantee covers the use of ab55624 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: Use at a concentration of 1-5 µg/ml.
    IHC-P: Use at a concentration of 5 µg/ml.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionThe lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases. Some of these enzymes require specific low-molecular mass, non-enzymic proteins: the sphingolipids activator proteins (coproteins).
      Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC and galactosylceramide by beta-galactosylceramidase (EC Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.
      Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC, GM1 gangliosides by beta-galactosidase (EC and globotriaosylceramide by alpha-galactosidase A (EC Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.
      Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC
    • Involvement in diseaseDefects in PSAP are the cause of combined saposin deficiency (CSAPD) [MIM:611721]; also known as prosaposin deficiency. CSAPD is due to absence of all saposins, leading to a fatal storage disorder with hepatosplenomegaly and severe neurological involvement.
      Defects in PSAP saposin-B region are the cause of leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) [MIM:249900]. MLD-SAPB is an atypical form of metachromatic leukodystrophy. It is characterized by tissue accumulation of cerebroside-3-sulfate, demyelination, periventricular white matter abnormalities, peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotr regression, seizures, cognitive decline and spastic quadriparesis.
      Defects in PSAP saposin-C region are the cause of atypical Gaucher disease (AGD) [MIM:610539]. Affected individuals have marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease, a lysosomal storage disorder.
      Defects in PSAP saposin-A region are the cause of atypical Krabbe disease (AKRD) [MIM:611722]. AKRD is a disorder of galactosylceramide metabolism. AKRD features include progressive encephalopathy and abnormal myelination in the cerebral white matter resembling Krabbe disease.
      Note=Defects in PSAP saposin-D region are found in a variant of Tay-Sachs disease (GM2-gangliosidosis).
    • Sequence similaritiesContains 2 saposin A-type domains.
      Contains 4 saposin B-type domains.
    • Post-translational
      This precursor is proteolytically processed to 4 small peptides, which are similar to each other and are sphingolipid hydrolase activator proteins.
      N-linked glycans show a high degree of microheterogeneity.
      The one residue extended Saposin-B-Val is only found in 5% of the chains.
    • Cellular localizationLysosome.
    • Information by UniProt
    • Database links
    • Alternative names
      • A1 activator antibody
      • Cerebroside sulfate activator antibody
      • Co-beta-glucosidase antibody
      • Component C antibody
      • CSAct antibody
      • Dispersin antibody
      • GLBA antibody
      • Glucosylceramidase activator antibody
      • Proactivator polypeptide antibody
      • Proactivator polypeptide precursor antibody
      • Prosaposin (sphingolipid activator protein 1) antibody
      • prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) antibody
      • Prosaposin antibody
      • Protein A antibody
      • Protein C antibody
      • PSAP antibody
      • SAP-1 antibody
      • SAP-2 antibody
      • SAP_HUMAN antibody
      • SAP1 antibody
      • Saposin A antibody
      • Saposin B antibody
      • Saposin B Val antibody
      • Saposin C antibody
      • Saposin D antibody
      • Saposin-D antibody
      • Saposins antibody
      • Sgp1 antibody
      • Sphingolipid activator protein 1 antibody
      • Sphingolipid activator protein 2 antibody
      • Sulfated glycoprotein 1 antibody
      • Sulfatide/GM1 activator antibody
      see all

    Anti-PSAP antibody images

    • PSAP antibody (ab55624) used in immunohistochemistry at 5ug/ml on formalin fixed and paraffin embedded human spleen tissue.

    • Predicted band size : 58 kDa
      Observed band size : 58 kDa
      Additional bands at : 48 kDa. We are unsure as to the identity of these extra bands.

    References for Anti-PSAP antibody (ab55624)

    ab55624 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab55624.
    Please use the links above to contact us or submit feedback about this product.